Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand? (2020)
- Authors:
- USP affiliated authors: FARIAS, KELEN CRISTINA RIBEIRO MALMEGRIM DE - FCFRP ; RODRIGUES, MARIA CAROLINA DE OLIVEIRA - FMRP
- Unidades: FCFRP; FMRP
- DOI: 10.3389/978-2-88963-472-9
- Subjects: TRANSPLANTES; CÉLULAS-TRONCO; DOENÇAS AUTOIMUNES
- Language: Inglês
- Imprenta:
- Publisher: Frontiers Media
- Publisher place: Lausanne
- Date published: 2020
- ISBN: 9782889634729
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?. . Lausanne: Frontiers Media. Disponível em: https://doi.org/10.3389/978-2-88963-472-9. Acesso em: 24 set. 2024. , 2020 -
APA
Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand? (2020). Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand? Lausanne: Frontiers Media. doi:10.3389/978-2-88963-472-9 -
NLM
Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand? [Internet]. 2020 ;[citado 2024 set. 24 ] Available from: https://doi.org/10.3389/978-2-88963-472-9 -
Vancouver
Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand? [Internet]. 2020 ;[citado 2024 set. 24 ] Available from: https://doi.org/10.3389/978-2-88963-472-9 - Editorial: immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
- New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement
- Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy
- Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: where do we stand?
- Teplizumab in relatives at risk for type 1 diabetes. [Carta]
- Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II
- Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers
- New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement
- CMV-specific clones may lead to reduced TCR diversity and relapse in systemic sclerosis patients treated with AHSCT [Carta]
- Thymus rejuvenation after autologous hematopoietic stem cell transplantation in patients with autoimmune diseases
Informações sobre o DOI: 10.3389/978-2-88963-472-9 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
